Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Compare Two Paracetamol Tablets

This study has been withdrawn prior to enrollment.
(Study was cancelled prior to enrolling any subjects.)
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: June 23, 2011
Last updated: July 5, 2016
Last verified: July 2016
This is a single dose pharmacoscintigraphic study investigating the differences in paracetamol absorption between two formulations.

Condition Intervention Phase
Healthy Subjects
Drug: Marketed paracetamol
Drug: Experimental paracetamol formulation
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: A Single Dose Pharmacoscintigraphic Study Investigating the Differences in Gastrointestinal Behavior and Paracetamol Absorption Between Sustained Release Formula and Standard Release Formula

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Time of onset and completion of disintegration based on release of radiolabeled markers in a fed condition [ Time Frame: Baseline to 12 hours post dosing ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To assess the gastrointestinal transit by qualitative scintigraphic analysis [ Time Frame: Baseline to 12 hours post dosing ] [ Designated as safety issue: No ]

Enrollment: 0
Study Start Date: April 2010
Estimated Study Completion Date: May 2010
Estimated Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Marketed paracetamol
Marketed formulation
Drug: Marketed paracetamol
marketed formulation
Experimental: Experimental paracetamol formulation
Experimental formulation
Drug: Experimental paracetamol formulation
Experimental formulation


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male subjects who are in good general health
  • Have not exceeded the limits of total radiation exposure (5mSv) allowed in any 12 month period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01381640

United Kingdom
BIO-IMAGES Research Ltd.
Glasgow, Scotland, United Kingdom, G63 0BX
Glasgow, Scotland, United Kingdom, G63 0BX
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT01381640     History of Changes
Other Study ID Numbers: A4040689 
Study First Received: June 23, 2011
Last Updated: July 5, 2016
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by GlaxoSmithKline:
healthy volunteer

Additional relevant MeSH terms:
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antipyretics processed this record on October 27, 2016